Project Grant R01AI195437
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $781K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $811,568 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize HIV-1 reservoir dynamics over two decades of antiretroviral therapy and model the biological forces that sustain persistent infection. The project conducts a multi-decade, multi-platform longitudinal study of latently infected CD4+ T cells and host immune responses in people living with...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $779,616 on April 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize the defective HIV-1 proviral reservoir in children and young adults living with perinatal HIV-1 infection. The research will determine the abundance and sequences of defective proviruses maintained during antiretroviral therapy, assess their ability to produce viral mRNA and proteins,...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $2.454 million on July 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct longitudinal, population-based research on evolving HIV transmission dynamics and threats to epidemic control in Africa. The recipient will assess changing HIV transmission dynamics in historically generalized epidemics as they concentrate in key and priority populations, examine...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $757,880 on June 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the impact of HIV-1 5' leader defects on plasma viremia, proviral dynamics, and immune responses. The project addresses the mechanisms by which defective HIV proviruses with 5' leader region mutations persist despite antiretroviral therapy and evade immune-mediated killing. The research...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $247,125 on May 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to isolate and functionally analyze monoclonal antibodies against the HIV-1 antisense protein ASP. The research isolates monoclonal antibodies (MAbs) against the ectodomain of ASP from elite controllers, viremic controllers, and people living with HIV-1 both on and off antiretroviral therapy. The work...
- The National Institute of Allergy and Infectious Diseases awarded $251,249 to The Johns Hopkins University on July 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize the structure and conformational dynamics of HIV-1 antisense protein (ASP), a membrane-associated viral protein implicated in viral entry. The research will acquire the first experimental structural information about ASP in lipid membranes using continuous wave and pulse electron spin...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $427,438 under Project Grant R21AI195115 on April 1, 2026, for research on identification and elimination of antigen-specific expanded clones in HIV latency. The research investigates clonal expansion of latently infected CD4+ T cells in response to cognate antigen, a process believed to contribute substantially to HIV reservoir size. The award funds a two-step intervention strategy: vaccination of...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Johns Hopkins University a $779,616 Project Grant (CFDA 93.855 – Allergy and Infectious Diseases Research) on April 10, 2026, to characterize the defective human immunodeficiency virus type 1 (HIV-1) proviral reservoir in children and adolescents living with perinatal HIV-1 infection. The primary deliverable is a comprehensive research investigation examining the abundance, composition,...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the University of Maryland Baltimore County $246,070 on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the phosphorylation and dephosphorylation of antiretroviral drugs tenofovir and emtricitabine in colonic tissue using mass spectrometry imaging-based enzyme histochemistry. The research addresses variability in clinical...
- The National Institute of Allergy and Infectious Diseases awarded Brigham & Women's Hospital Inc. $894,998 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate intrinsic CD4 T cell barriers to HIV-1 latency reversal. The research addresses HIV-1 persistence in CD4 T cells despite effective antiretroviral therapy by examining post-transcriptional mechanisms that constrain productive viral gene expression. The investigator will integrate...